Argenx will spend $2.2 billion to buy Forte Biosciences and its anti-CD122 monoclonal antibody that’s under investigation for autoimmune diseases.
Argenx will spend $2.2 billion to buy Forte Biosciences and its anti-CD122 monoclonal antibody that’s under investigation for autoimmune diseases.
The Belgian-Dutch pharma said Monday …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune…
Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug…
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
O negócio permite adicionar ao portfólio o medicamento experimental FB102, da Forte, para o qual a empresa enxerga potencial de…
Grâce à sa confortable trésorerie, argenx reprend Forte Biosciences, une société américaine également spécialisée dans les…
En vue d'élargir son pipeline dans l'immunologie, argenx met la main sur une biotech américaine pour 2,2 milliards de dollars. Le…
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
